Price
$0.3989
Decreased by -5.09%
Dollar Volume
153.17 K
ADR%
13.8
Earnings Report Date (estimate)
Nov 14, 22 (-0.12)
Market Cap.
10.71 M
Shares Float
22.82 M
Shares Outstanding
26.85 M
Beta
0.59
Price / Earnings
-0.46
BPR
13.65
20D Range
0.30 0.57
50D Range
0.20 0.57
200D Range
0.20 2.08
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.12
Increased by +45.45%
-0.18
Increased by +33.33%
Aug 15, 22 -0.16
Increased by +36.00%
-0.14
Decreased by -14.29%
May 16, 22 -0.13
Increased by +45.83%
-0.17
Increased by +23.53%
Mar 28, 22 -0.28
Decreased by -16.67%
-0.21
Decreased by -33.33%
Nov 15, 21 -0.22
Decreased by -37.50%
-0.22
Aug 12, 21 -0.25
Decreased by -19.05%
-0.20
Decreased by -25.00%
Mar 22, 21 -0.24
Increased by +11.11%
-0.25
Increased by +4.00%
Nov 13, 20 -0.24
Increased by +11.11%
-0.18
Decreased by -33.33%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-3.11 M
Increased by +27.99%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-3.85 M
Increased by +13.36%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-2.91 M
Increased by +39.84%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-5.83 M
Decreased by -68.07%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-4.32 M
Decreased by -29.44%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-4.44 M
Decreased by -145.21%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-4.83 M
Decreased by -112.30%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-3.47 M
Decreased by -68.53%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.